FORM PTO-1390 (REV 10-95) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER: IVD 994

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371

U. S. APPLICATION NO. (If known, see 37 CFR 1.5): 09/446601

INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
PCT/FR98/01285	19 June 1998	23 June 1997

TITLE OF INVENTION: **Solid Pharmaceutical Composition Containing Benzofuran Derivatives**

APPLICANT(S) FOR DO/EO/US

Bernard ABRAMOVICI, Jean-Claude GAUTIER, Jean-Claude GROMENIL, Jean-Marie MARRIER

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND or SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1)).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
   a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
   b. ☒ has been transmitted by the International Bureau.
   c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ A translation of the International Application into English (35 U.S.C. 371 (c)(2)).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
   a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
   b. ☐ have been transmitted by the International Bureau.
   c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
   d. ☒ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).
9. ☒ An unexecuted oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern document(s) or information included:

11. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A FIRST preliminary amendment.
    ☐ A SECOND or SUBSEQUENT preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☒ Other items or information:
    Citation of References

U.S. APPLICATION NO (if known, see 37 CFR 1 5)	INTERNATIONAL APPLICATION NO	ATTORNEY'S DOCKET NUMBER
09/446601	PCT/FR98/01285	IVD 994

17. ☒ The following fees are submitted:

	CALCULATIONS PTO USE ONLY	
BASIC NATIONAL FEE (37 CFR 1. 492 (a)(1)-(5)):		
Search Report has been prepared by the EPO or JPO. $840.00		
International preliminary examination fee paid to USPTO (37CFR 1.482) $670.00		
No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) $760.00		
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO $970.00		
International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4). $96.00		
ENTER APPROPRIATE BASIC FEE AMOUNT =	**$ 840.00**	
Surcharge of **$130.00** for furnishing the oath or declaration later than [ ]20 [ ]30 months from the earliest claimed priority date (37 CFR 1.492(e)).	$	

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	22 - 20 =	2	x $18.00	**$ 36.00**	
Independent claims	1 - 3 =	0	x $78.00		
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ $260.00	$	
			TOTAL OF ABOVE CALCULATIONS =	**$ 876.00**	
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).				$	
			SUBTOTAL =	**$ 876.00**	
Processing fee of **$130.00** for furnishing the English translation later than [ ]20 [ ]30 months from the earliest claimed priority date (37 CFR 1.492 (f)). +				$	
			TOTAL NATIONAL FEE =	**$ 876.00**	
Fee for recording the enclosed assignment (37 CFR 1.21(h). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). **$40.00** per property +				$	
			TOTAL FEES ENCLOSED =	**$ 876.00**	
			Amount to be refunded:	$	
			Charged	**$ 876.00**	

a. ☐ A check in the amount of $_____ to cover the above fees is enclosed.

b. ☒ Please charge my Deposit Account No. **19-0091** in the amount of **$ 876.00** to cover the above fees. A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. **19-0091**. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO

Michael D. Alexander
Patent Department
Sanofi-Synthelabo Inc.
9 Great Valley Parkway
P.O. Box 3026
Malvern, PA 19355

Paul E. Dupont 12/22/99
SIGNATURE DATE

Paul E. Dupont
NAME

27,438
REGISTRATION NUMBER

(610) 889-8802
TELEPHONE NUMBER

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Filing under 35 U.S.C. § 371
Corresponding to International
Application Serial No.: PCT/FR98/01285

Applicants: Bernard ABRAMOVICI, Jean-Claude GAUTIER, Jean-Claude GROMENIL and Jean-Marie MARRIER

International Filing Date: 16 June 1998

For: SOLID PHARMACEUTICAL COMPOSITION CONTAINING BENZOFURAN DERIVATIVES

CERTIFICATE UNDER 37 C.F.R. 1.10

Express Mail Label Number: EL301242810US

Date of Deposit: December 22, 1999

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service on the date indicated above and is addressed to: Asst. Commissioner for Patents, Box PCT, Attn: EO/US, Washington, DC 20231.

Amy L. Bean

Signature

Assistant Commissioner for Patents
Box PCT
Attn: EO/US
Washington, D.C. 20231

Dear Sir:

PRELIMINARY AMENDMENT

Please amend the above-identified application as follows prior to calculation of the filing fee:

In the Specification:

At page 1, preceding line 1, add the following title:

-- Solid Pharmaceutical Compositions Containing Benzofuran Derivatives --.

At page 17, table b), line 2 of the column entitled Ingredients, amend "400 mg" to read -- 200 mg --.

In the Claims:

Please amend the claims as follows:

1. (amended) [Solid] A solid pharmaceutical composition for oral administration [characterized in that it comprises] comprising a benzofuran derivative with antiarrhythmic activity, or [one of the] a pharmaceutically acceptable [salts] salt thereof, as an active principle, and a pharmaceutically acceptable nonionic hydrophilic surfactant optionally in combination with one or more pharmaceutical excipients.

2. (amended) [Pharmaceutical] A pharmaceutical composition according to Claim [1, characterized in that] 4, wherein the benzofuran derivative [with antiarrhythmic activity] is dronedarone [or one of the pharmaceutically acceptable salts thereof] hydrochloride.

3. (amended) [Pharmaceutical] A pharmaceutical composition according to Claim [1, characterized in that] 4, wherein the benzofuran derivative [with antiarrhythmic activity] is amiodarone [or one of the pharmaceutically acceptable salts thereof] hydrochloride.

4. (amended) [Pharmaceutical] A pharmaceutical composition according to [one of Claims 1 to 3, characterized in that] Claim 14 wherein the pharmaceutically acceptable salt is the hydrochloride.

5. (amended) [Pharmaceutical] A pharmaceutical composition according to [one of Claims 1 to 4, characterized in that] Claim 1 wherein the nonionic hydrophilic surfactant is [chosen] selected from the group consisting of poloxamers, polyethyoxylated castor oils, ethoxylated polysorbates and polyethylene hydroxystearates.

6. (amended) [Pharmaceutical] A pharmaceutical composition according to Claim 5[, characterized in that] wherein the nonionic hydrophilic surfactant is [chosen] selected from the group consisting of poloxamer 124, poloxamer 188, poloxamer 237, poloxamer 338, poloxamer 407, polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80 and the products Cremophor® RH 40 and Solutol® HS15.

7. (amended) [Pharmaceutical] A pharmaceutical composition according to Claim [5 or 6, characterized in that] 15 wherein the nonionic hydrophilic surfactant is poloxamer 407.

8. (amended) [Pharmaceutical] A pharmaceutical composition according to [one of Claims 1 to 7, characterized in that] Claim 6 wherein the nonionic hydrophilic [agent] surfactant is present in a proportion of from 1% to 50% by weight of the active principle in base form.

9. (amended) [Pharmaceutical] A pharmaceutical composition according to Claim 8, in tablet or gelatin capsule form, [characterized in that] wherein the nonionic hydrophilic surfactant is present in a proportion of from 1% to 20% by weight of the active principle in base form.

10. (amended) [Pharmaceutical] A pharmaceutical composition according to Claim 9, in tablet or gelatin capsule form, [characterized in that] wherein the nonionic hydrophilic surfactant is present in a proportion of from 5% to 15% by weight of the active principle in base form.

11. (amended) [Pharmaceutical] A pharmaceutical composition according to [one of Claims 1 to 10, characterized in that it contains] Claim 8 containing from 50 to 500 mg of active principle.

12. (amended) [Pharmaceutical] A pharmaceutical composition according to Claim 11, in tablet or gelatin capsule form, [characterized in that it contains] containing from 200 to 400 mg of active principle.

13. (amended) [Pharmaceutical] A pharmaceutical composition according to [one of Claims 1 to] Claim 12, in tablet or gelatin capsule form, [characterized in that it contains] containing from 200 to 400 mg of active principle, calculated in base form, and 10% by weight of nonionic hydrophilic surfactant relative to the active principle in base form.

Please add the following new claims:

14. A pharmaceutical composition according to Claim 1 wherein the benzofuran derivative is selected from the group consisting of amiodarone and dronedarone or a pharmaceutically acceptable salt thereof.

15. A pharmaceutical composition according to Claim 6 wherein the benzofuran derivative is selected from the group consisting of amiodarone and dronedarone or a pharmaceutically acceptable salt thereof.

16. A pharmaceutical composition according to Claim 7 wherein the benzofuran derivative is dronedarone hydrochloride.

17. A pharmaceutical composition according to Claim 10 wherein the benzofuran derivative is selected from the group consisting of amiodarone and dronedarone or a pharmaceutically acceptable salt thereof.

18. A pharmaceutical composition according to Claim 17 wherein the nonionic hydrophilic surfactant is poloxamer 407.

19. A pharmaceutical composition according to Claim 18 wherein the benzofuran derivative is dronedarone hydrochloride.

20. A pharmaceutical composition according to Claim 13 wherein the active principle is selected from the group consisting of amiodarone and dronedarone or a pharmaceutically acceptable salt thereof and the nonionic hydrophilic surfactant is poloxamer 407.

21. A pharmaceutical composition according to claim 20 wherein the nonionic hydrophilic surfactant is poloxamer 407.

22. A pharmaceutical composition according to claim 21 wherein the active principle is dronedarone hydrochloride.

REMARKS

The specification is amended at page 1 to add a title, and at page 17 to correct an obvious typographical error.

The title is taken from paragraph 1 at page 1, and the error at page 17 is clearly obvious from the context. Thus, given the molecular weights of dronedarone (556.38) and dronedarone hydrochloride (592.38), it is obvious that 213 mg of the hydrochloride corresponds to 200 mg (and not 400 mg) of the free base.

Claims 1-13 are amended to put them in a format consistent with U.S. practice, and/or to eliminate multiple dependencies, and/or to modify dependencies as appropriate.

New claims 14-22 are added. Support for these claims is found as follows.

New claim 14 combines original claims 2 and 3 in Markush format and original claims 2 and 3 as now amended are directed to the preferred species as claimed by original claim 4.

New claim 15 is directed to the subject matter of original claim 6 as dependent from original claims 2 and 3.

New claim 16 is directed to the subject matter of original claim 7 as dependent from original claims 2 and 4.

New claim 17 is directed to the subject matter of original claim 10 as dependent from original claims 2 and 3.

New claim 18 is directed to the subject matter of original claim 10 as dependent from original claims 2, 3 and 7.

New claim 19 is directed to the subject matter of original claim 10 as dependent from original claims 2, 4 and 7.

New claim 20 is directed to the subject matter of original claim 13 as dependent from original claims 2 and 3.

New claim 21 is directed to the subject matter of original claim 13 as dependent from original claims 2, 3 and 7.

New claim 22 is directed to the subject matter of original claim 13 as dependent from original claims 2, 4 and 7.

Respectfully submitted,

Date: December 22, 1999

Paul E. Dupont
Reg. No. 27,438

Address
Patent Department
Sanofi-Synthelabo Inc.
9 Great Valley Parkway
P.O. Box 3026
Malvern, PA 19355
Telephone No. (610) 889-8802
Facsimile: (610) 889-8799

The present invention relates generally to a novel pharmaceutical composition for oral administration containing a benzofuran derivative as active principle.

More precisely, the invention relates to a solid pharmaceutical composition for oral administration containing a benzofuran derivative with antiarrhythmic activity as active principle.

In the context of the present invention, the expression "benzofuran derivative with antiarrhythmic activity" is understood to denote a benzofuran compound chosen from those described in US patents 3,248,401 and 5,223,510 and European patent EP 338,746, as well as in patent applications WO 88/07996, WO 89/02892, WO 90/02743 and WO 94/29289.

Of all of these compounds, mention may preferably be made of 2-n-butyl-3-[4-(3-di-n-butylaminopropoxy)benzoyl]-5-methylsulphonamidobenzofuran or dronedarone and the pharmaceutically acceptable salts thereof described in US patent 5,223,510, as well as 2-n-butyl-3-(3,5-diiodo-4-diethylaminoethoxybenzoyl)-benzofuran or amiodarone and the pharmaceutically acceptable salts thereof described in US patent 3,248,401.

Similarly, the expression "solid pharmaceutical composition" is understood to refer essentially to a pharmaceutical composition formed entirely of pulverulent solid ingredients which can be tabletted at room temperature, comprising the active principle and the excipients, these ingredients being essentially in powder form.

Consequently, the so-called semi-solid pharmaceutical compositions, formed of substances in pasty or waxy form when they are brought to moderate temperature (< 70°C), do not form part of the invention.

The antiarrhythmic compounds used in the context of the invention, in particular dronedarone and amiodarone in the form of their hydrochloride, are characterized by low solubility in aqueous medium.

For example, the solubility curve of dronedarone hydrochloride at room temperature and as a function of the pH reveals a maximum solubility around pH values of 3 to 5, of about 1 to 2 mg/ml, but very low solubility at pH values of about 6 to 7, since it is only 10 µg/ml at pH = 7.

As regards amiodarone hydrochloride, its solubility at room temperature is from 0.3 to 0.9 mg/ml in the pH range from 3 to 4, and is a few µg/ml at pH = 7.

Thus, it is possible to dissolve 400 mg of dronedarone hydrochloride in 200 ml of aqueous medium buffered to pH = 4 (aqueous 0.1 M NaH_2PO_4 solution).

On the other hand, in this medium diluted to 1/10 with an aqueous solution buffered to pH = 7 (aqueous 0.1 M Na_2HPO_4 solution), dronedarone hydrochloride precipitates (pH of the final medium: 6.7).

Since these solubility conditions are similar to those recorded in the gastrointestinal tract, it can be assumed that dronedarone hydrochloride risks being subjected, in the stomach, to acidic conditions which are favourable to its solubilization, but, on the other hand, risks encountering a medium of pH = 6 to 7 once it enters the intestine, i.e. a non-solubilizing medium in which it will precipitate.

This behaviour in intestinal medium probably makes it possible to explain **in vivo** the low bioavailability of dronedarone hydrochloride and the differences observed after administration with or without food, since it has been observed that the bioavailability of dronedarone hydrochloride in dogs and in man is increased after the intake of food, in particular fats, which can greatly modify the precipitation kinetics of this active principle and also help to place it in emulsion form.

Since the absorption of food gives rise to the secretion of bile salts, which are anionic surfactants, it appears that this might have a favourable influence on the solubilization of dronedarone hydrochloride.

However, tests carried out to this end showed, in contrast, that this active principle precipitates in the presence of bile salts such as sodium taurocholate.

The development of an oral pharmaceutical composition of dronedarone, of amiodarone or of pharmaceutically acceptable salts thereof, which is capable of avoiding the precipitation of the active principle in neutral medium and of reducing the variability of absorption of this active principle into the plasma, i.e. of providing an acceptable bioavailability independently of the presence of food, remains of fundamental interest.

It has now been found, surprisingly, that the combination of a nonionic hydrophilic surfactant with dronedarone, amiodarone or the pharmaceutically acceptable salts thereof, makes it possible to maintain the solubilization of this active principle in neutral medium and to reduce, in man, its variability of absorption into the blood.

This observation is all the more surprising since preliminary tests carried out on dogs did not make it possible to show that a nonionic hydrophilic surfactant was capable of increasing the fasted bioavailability of dronedarone hydrochloride, and at the same time of reducing the variability of absorption of this active principle into the plasma.

Thus, the invention relates to a solid pharmaceutical composition for oral administration comprising a benzofuran derivative with antiarrhythmic activity, or one of the pharmaceutically acceptable salts thereof, as an active principle, and to a pharmaceutically acceptable nonionic hydrophilic surfactant optionally in combination with one or more pharmaceutical excipients.

This pharmaceutical composition can be in any solid pharmaceutical form which is suitable for oral administration, such as a tablet which may or may not be splittable, a granule, a gelatin capsule or a powder in a unit sachet.

Consequently, another subject of the invention relates to the above oral pharmaceutical composition in tablet, granule, gelatin capsule or powder form.

The nonionic hydrophilic surfactant used in the composition of the invention can be chosen from:

- ethyleneoxide/propyleneoxide copolymers referred to hereinbelow as poloxamers, such as poloxamer 124 sold under the brand name Synperonic® PE/L44; poloxamer 188 sold under the brand name Pluronic® F68 or Synperonic® PE/F68; poloxamer 237 sold under the brand name Pluronic® F87 or Synperonic® PE/F87; poloxamer 338 sold under the brand name Synperonic® PE/F108 or poloxamer 407 sold under the brand name Pluronic® F127, Synperonic® PE/F127 or Lutrol® F127.
- polyethoxylated castor oils such as those sold under the brand name Cremophor® RH40.
- ethoxylated polysorbates, such as polysorbate 20, polysorbate 40, polysorbate 60 and polysorbate 80 sold respectively under the brand names Tween® 20, Tween® 40, Tween® 60 and Tween® 80.
- or alternatively polyethylene hydroxystearates such as polyethylene hydroxystearate 660 sold under the brand name Solutol® HS15.

As preferred surfactant, mention may be made of poloxamer 407.

Usually, the nonionic hydrophilic surfactant in question is incorporated into the solid compositions of the invention in a proportion of from 1% to 50% by weight relative to the active principle in base form, irrespective of the unitary or non-unitary pharmaceutical form adopted for packaging them.

For the preparation of solid compositions in tablet form or packaged in gelatin capsule form, from 1% to 20% by weight of surfactant relative to the active principle in base form, preferably from 5% to 15%, will be used, for example.

As a non-limiting guide, the amount of active principle can range from 50 to 500 mg per admini-

stration unit in tablet form, which entails the incorporation of an amount of surfactant of between 0.5 and 100 mg. These amounts of surfactant prove to be perfectly acceptable with pharmaceutical forms such as tablets or gelatin capsules, whose sizes will remain compatible with oral administration.

In a preferred manner, solid pharmaceutical compositions of the invention, for example in tablet or gelatin capsule form, can contain from 200 to 400 mg of active principle calculated in the form of base and from 5% to 15%, more particularly 10%, by weight of nonionic hydrophilic surfactant relative to the active principle in base form.

For packaging in the form of powder in a unit sachet, from 1% to 50% by weight of nonionic hydrophilic surfactant relative to the active principle in base form may be used.

Besides the surfactant in question, the compositions in solid form according to the invention will comprise other pharmaceutical excipients generally used in the development of oral pharmaceutical forms.

These substances are entirely known to those skilled in the art, who can readily select them depending on the type of oral composition chosen.

As nonlimiting examples, mention may be made of binders, generally cellulose derivatives such as methylcellulose, hydroxyethylcellulose or methylhydroxypropylcellulose, or alternatively macrogols such as macrogol 6000; flow agents such as colloidal silica; vinylpyrrolidone polymers or copolymers such as polyvinylpyrrolidone; diluents such as lactose or mannitol; starches such as wheat starch or corn starch; lubricants such as magnesium stearate or sodium stearyl fumarate.

The compositions of the invention can be prepared by carrying out known processes involving, in particular, techniques of granulation via a wet or dry route, via fusion or via direct tabletting for the formation of tablets.

For example, tablets can be prepared by wet granulation by mixing together, at the initial stage, all of the ingredients, including the active principle and the surfactant, except for, however, the lubricant.

Operations of wetting with purified water, drying and sizing of the granule obtained, lubrication and tabletting or direct filling of gelatin capsules are then carried out.

According to variants of this method:

a) all of the ingredients, including the active principle, except for the surfactant and the lubricant, are mixed together at the initial stage and the process continues by operations of wetting with an aqueous solution of the surfactant, granulation, drying, sizing, lubrication and tabletting or direct filling of gelatin capsules,

or

b) all of the ingredients, including the active principle and the surfactant, except for the binder and the lubricant, are mixed together at the initial stage and the process then continues by operations of wetting with an aqueous solution of the binder, granulation, drying, sizing, lubrication and tabletting or direct filling of gelatin capsules.

These methods can also be modified by including a continuous granulation process which uses the fluidized airbed technique at the stage of the wetting operation.

In addition, it is also possible to use a process in which all of the ingredients are mixed together in the initial stage, except for the lubricant, which is heated to a temperature of about 60°C to 65°C. Operations of hot granulation, sizing after cooling, lubrication and tabletting or direct filling of gelatin capsules are then carried out.

According to dry granulation techniques, all of the ingredients, including the active principle and the surfactant, except for the lubricant, are first mixed together and the process then continues with operations

of screening, compacting, sizing, lubrication and tabletting or direct filling of gelatin capsules.

Finally, the process can be performed by direct tabletting using the following sequence of operations: mixing of the ingredients including the active principle and the surfactant, except the lubricant, followed by screening and mixing, then lubrication and finally tabletting or direct filling of gelatin capsules.

The characteristics and advantages of the oral compositions according to the invention will become apparent in the light of the description hereinbelow using specific oral compositions given by way of example with reference to the attached drawings.

I. <u>Test of maintenance in solution at pH = 6.7</u>

<u>A. Active principle alone</u>

Solutions were prepared containing 2 mg/ml of dronedarone hydrochloride in hydrogenphosphate (NaH_2PO_4) buffered medium at pH = 4.5 for 2 hours at 37°C in the presence or absence of x% of nonionic hydrophilic surfactant to be studied, calculated on a weight basis relative to the active principle in base form.

This solution was then diluted to 1/10th in a neutral phosphate medium (Na_2HPO_4+NaH_2PO_4), the pH of the final solution being 6.7.

After 2 hours at 37°C, the solution was filtered through an Acrodisc® brand 5 µm filter and the active principle in solution was assayed by UV spectrometry.

The following results were thus obtained:

Surfactant	x%	% of dronedarone hydrochloride in solution
TWEEN® 20	50	65
TWEEN® 40	50	63
TWEEN® 60	50	74
TWEEN® 80	50	69
Synperonic® PE/F68	50	74
Synperonic® PE/F87	50	75
Synperonic® PE/F127	50	95
CREMOPHOR® RH 40	50	64
SOLUTOL® HS 15	50	59
Synperonic® PE/F127	10	78
Synperonic® PE/F127	5	63
-	-	5

B. Active principle in tablet form

Solutions were prepared containing 2 mg/ml of dronedarone hydrochloride (expressed in base form) in hydrogenphosphate (NaH_2PO_4) buffered medium at pH = 4.5 or containing 2 mg/ml of amiodarone hydrochloride, in a buffered medium at pH = 3.5.

These solutions were obtained by dissolving dronedarone hydrochloride tablets or amiodarone hydrochloride tablets containing or not containing 10% of poloxamer 407 (Synperonic® PE/F127), i.e.:

	Tablets	
	α (mg)	A (mg)
Dronedarone hydrochloride (corresponding to 400 mg of base)	426	426
Methylhydroxypropylcellulose	12	12
Lactose monohydrate	63.6	63.6
Modified corn starch	60	60
Polyvinylpyrrolidone	30	30
Anhydrous colloidal silica	2.4	2.4
Synperonic® PE/F127	-	40
Magnesium stearate	6	6
	600	640

	Tablets	
	β (mg)	B (mg)
Amiodarone hydrochloride	200	200
Lactose monohydrate	71	71
Modified corn starch	66	66
Crosslinked polyvinylpyrrolidone	6	6
Anhydrous colloidal silica	2.4	2.4
Synperonic® PE/F127	-	20
Magnesium stearate	4.6	4.6
	350	370

After 2 hours of dissolution at 37°C, these solutions are diluted to 1/10th in a neutral phosphate medium (Na_2HPO_4 + NaH_2PO_4), the pH of the final solution being 6.7.

The test was then continued as described in paragraph A above and the following results were obtained:

	% of dronedarone hydrochloride in solution
Tablet α	4.6
Tablet A	80

	% of amiodarone hydrochloride in solution
Tablet β	55
Tablet B	100

These results show that, in tablets, the incorporation of 10% by weight of poloxamer 407, relative to the base dronedarone or to the amiodarone hydrochloride, makes it possible to maintain from 80% to 100% of active principle in solution for 2 hours.

II. Pharmacokinetic tests

Comparative tests with dronedarone hydrochloride were carried out on 16 male volunteers, 8 of whom had been fasted and the other 8 not.

These tests were performed using tablets of the invention: one at 10% by weight of surfactant relative to the weight of dronedarone in base form (tablet A above), the other at 5% by weight of the same surfactant (tablet C below), i.e.:

Tablet C	mg
Dronedarone hydrochloride (corresponding to 400 mg of base)	426
Methylhydroxypropylcellulose	12
Lactose monohydrate	63.6
Modified corn starch	60
Polyvinylpyrrolidone	30
Anhydrous colloidal silica	2.4
Synperonic® PE/F127	20
Magnesium stearate	6
	620

compared with compositions free of nonionic hydrophilic surfactant, i.e.:

a) tablet α above

b) gelatin capsule having a composition of formulation:

	mg
Dronedarone hydrochloride (corresponding to 200 mg of base)	213
Modified corn starch	86.2
Lactose monohydrate	129.2
Talc	48
Anhydrous colloidal silica	1.2
Magnesium stearate	2.4
	480

Each of these volunteers received a single dose of dronedarone hydrochloride equivalent to 800 mg of base in the form of the above gelatin capsule, of tablet α, of tablet A or of tablet C, each single dose being separated from the following one by an interval of 7 days.

Plasmatic dronedarone assays were then carried out on each individual 0, 1, 2, 3, 4, 5, 6, 7, 10, 12, 16 and 24 hours after administration and the maximum concentrations of this active principle (C max in ng/ml) were noted, as well as the area under the curves defined by the concentration of the active principle as a function of time (AUC in ng.h/ml).

This procedure was repeated in a second series of tests carried out on the same two groups of 8 alternate volunteers, i.e. the 8 fasted volunteers carrying out the test while not fasted, and vice versa.

The results obtained when fasted are reproduced in the attached Figure I and those obtained while not fasted appear in the attached Figure II, in which:

a) the curve referred to as "gelatin capsule" represents the average plasmatic concentration obtained with the composition in the form of a gelatin capsule
b) the curve referred to as "tablet α" represents the average plasmatic concentration obtained with the tablet α
c) the curve referred to as "tablet A" represents the average plasmatic concentration obtained with the tablet A containing 10% of Synperonic® PE/F127 surfactant
d) the curve referred to as "tablet C" represents the average plasmatic concentration obtained with tablet C containing 5% of Synperonic® PE/F127 surfactant.

From these curves, it is possible in particular:

1) to deduce that the presence of the surfactant increases the fasted bioavailability of the active principle.

2) to draw up the following comparative tables from the results of the C max and AUC values obtained with each formulation in the non-fasted volunteers compared with the corresponding results in the fasted volunteers, relative to 1:

TABLE I

Ratio of the C max values	Treatment			
	Gelatin capsule	Tablet α	Tablet C	Tablet A
Fasted	1	1	1	1
Not fasted	12.5	10.3	4.8	2.7

TABLE II

Ratio of the AUC values	Treatment			
	Gelatin capsule	Tablet α	Tablet C	Tablet A
Fasted	1	1	1	1
Not fasted	16.7	8.9	5.3	3.2

These tables show that the surfactant is capable of reducing by a factor of 2 to 5 the variations in maximum plasmatic concentrations of active principle obtained in non-fasted individuals compared with fasted individuals (Table I).

Similarly, it may be concluded that the large variations in bioavailability recorded with surfactant-free compositions could be reduced by a factor of 1.5 to 5 (Table II).

The following non-limiting examples illustrate the invention.

EXAMPLE 1

Dronedarone hydrochloride tablet

Dronedarone hydrochloride tablets of the formulation below were prepared:

Ingredients	mg	%
Dronedarone hydrochloride (corresponding to 400 mg of base)	426	65.5
Methylhydroxypropylcellulose	21.1	3.25
Lactose monohydrate	46.55	7.2
Modified corn starch	45.5	7
Polyvinylpyrrolidone	65	10
Poloxamer 407	40	6.15
Anhydrous colloidal silica	2.6	0.4
Magnesium stearate	3.25	0.5
	650	100

by applying the process below:

After screening, 724.2 g of dronedarone hydrochloride, 35.9 g of methylhydroxypropylcellulose, 79.1 g of lactose monohydrate, 77.4 g of corn starch and 82.9 g of polyvinylpyrrolidone are mixed together.

The mixture is moistened with 68 g of poloxamer 407 (Synperonic® PE/F127) as a solution in 408 g of purified water, and this mixture is granulated. The wet mass is dried at a temperature of about 50°C and is sized on screens with a mesh size of 1.250 mm. 27.6 g of polyvinylpyrrolidone, 4.4 g of anhydrous colloidal silica and 5.5 g of magnesium stearate are mixed with the granule thus sized and the final mixture is then tabletted in a proportion of 650 mg per unit.

EXAMPLE 2

Dronedarone hydrochloride tablet

Dronedarone hydrochloride tablets of identical formulation to that of Example 1 were prepared by applying the process below:

After screening, 724.2 g of dronedarone hydrochloride, 35.9 g of methylhydroxypropylcellulose, 79.1 g of lactose monohydrate, 77.4 g of corn starch, 82.9 g of polyvinylpyrrolidone and 68 g of poloxamer 407 (Synperonic® PE/F127) are mixed together. The mixture is then moistened with purified water, after which the process is carried out in the same way as in Example 1 in order to obtain tablets with a weight of 650 mg per unit.

EXAMPLE 3

Dronedarone hydrochloride tablet

Dronedarone hydrochloride tablets of identical formulation to that of Example 1 were prepared by applying the process below:

After screening, 724.2 g of dronedarone hydrochloride, 79.1 g of lactose monohydrate, 77.4 g of corn starch, 82.9 g of polyvinylpyrrolidone and 68 g of poloxamer 407 (Synperonic® PE/F127) are mixed. The mixture is moistened with 35.9 g of methylhydroxypropylcellulose as a solution in 408 g of purified water and this mixture is granulated. The wet mass is dried at a temperature of about 50°C and is sized on a screen with a mesh size of 1.250 mm. 27.6 g of polyvinylpyrrolidone, 4.4 g of anhydrous colloidal silica and 5.5 g of magnesium stearate are mixed with the granule thus sized and the final mixture is then tabletted in a proportion of 650 mg per unit.

EXAMPLE 4

Dronedarone hydrochloride tablet

Dronedarone hydrochloride tablets of the formulation below were prepared:

Ingredients	mg	%
Dronedarone hydrochloride (corresponding to 400 mg of base)	426	65.5
Microcrystalline cellulose	65	10
Anhydrous colloidal silica	2.6	0.4
Anhydrous lactose	42.65	6.6
Polyvinylpyrrolidone	13	2
Poloxamer 407	40	6.15
Macrogol 6000	57.5	8.85
Magnesium stearate	3.25	0.5
	650	100

by carrying out the process below:

After screening, 724.2 g of dronedarone hydrochloride, 110.5 g of microcrystalline cellulose, 2.2 g of anhydrous colloidal silica, 72.5 g of anhydrous lactose, 22.1 g of polyvinylpyrrolidone, 68 g of poloxamer 407 (Synperonic® PE/F127) and 97.8 g of macrogol 6000 are mixed together. The temperature of the mixture is raised to 65°C in a thermostatically-controlled tank, with slow stirring. This mixture is granulated with fast stirring, cooled to room temperature and then sized. 2.2 g of anhydrous colloidal silica and 5.5 g of magnesium stearate are then mixed with the sized granule and the final mixture is tabletted in a proportion of 650 mg per unit.

This granulation process can also be carried out in apparatus with a fluidized airbed.

EXAMPLE 5

Dronedarone hydrochloride tablet

Dronedarone hydrochloride tablets of identical formulation to that of Example 4 were prepared by applying the process below:

After sizing, 724.2 g of dronedarone hydrochloride, 110.5 g of microcrystalline cellulose, 2.2 g of anhydrous colloidal silica, 72.5 g of anhydrous lactose, 22.1 g of polyvinylpyrrolidone, 68 g of molten poloxamer 407 (Synperonic® PE/F127) and 97.8 g of molten macrogol 6000 are mixed together.

The process is then carried out in the same way as in Example 4, in order to obtain tablets with a weight of 650 mg per unit.

EXAMPLE 6

Dronedarone hydrochloride tablet

Dronedarone hydrochloride tablets of identical formulation to that of Example 4, but after replacing the macrogol 6000 with an equivalent amount of poloxamer 407, were prepared by applying the process below:

After sizing, 724.2 g of dronedarone hydrochloride, 110.5 g of microcrystalline cellulose, 2.2 g of anhydrous colloidal silica, 72.5 g of anhydrous lactose, 22.1 g of polyvinylpyrrolidone and 166.7 g of poloxamer 407 (Synperonic® PE/F127) are mixed together.

The process is then performed in the same way as in Example 4, in order to obtain tablets with a weight of 650 mg per unit.

EXAMPLES 7 and 8

Following the processes described above, tablets of the formulation below were prepared:

a)

Ingredients	mg	%
Dronedarone hydrochloride (corresponding to 400 mg of base)	426	65.6
Microcrystalline cellulose	26	4
Corn starch	45.5	7
Polyvinylpyrrolidone	65	10
Poloxamer 407	40	6.1
Anhydrous colloidal silica	2.6	0.4
Magnesium stearate	3.25	0.5
Lactose monohydrate	41.65	6.4
	650	100

b)

Ingredients	mg	%
Dronedarone hydrochloride (corresponding to 400 mg of base)	213	65.6
Microcrystalline cellulose	13	4
Corn starch	22.75	7
Polyvinylpyrrolidone	32.5	10
Poloxamer 407	20	6.1
Anhydrous colloidal silica	1.3	0.4
Magnesium stearate	1.625	0.5
Lactose monohydrate	20.825	6.4
	325	100

CLAIMS

1. Solid pharmaceutical composition for oral administration characterized in that it comprises a benzofuran derivative with antiarrhythmic activity, or one of the pharmaceutically acceptable salts thereof, as an active principle, and a pharmaceutically acceptable nonionic hydrophilic surfactant optionally in combination with one or more pharmaceutical excipients.

2. Pharmaceutical composition according to Claim 1, characterized in that the benzofuran derivative with antiarrhythmic activity is dronedarone or one of the pharmaceutically acceptable salts thereof.

3. Pharmaceutical composition according to Claim 1, characterized in that the benzofuran derivative with antiarrhythmic activity is amiodarone or one of the pharmaceutically acceptable saltfs thereof.

4. Pharmaceutical composition according to one of Claims 1 to 3, characterized in that the pharmaceutically acceptable salt is the hydrochloride.

5. Pharmaceutical composition according to one of Claims 1 to 4, characterized in that the nonionic hydrophilic surfactant is chosen from poloxamers, polyethyoxylated castor oils, ethoxylated polysorbates and polyethylene hydroxystearates.

6. Pharmaceutical composition according to Claim 5, characterized in that the nonionic hydrophilic surfactant is chosen from poloxamer 124, poloxamer 188, poloxamer 237, poloxamer 338, poloxamer 407, polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80 and the products Cremophor® RH 40 and Solutol® HS15.

7. Pharmaceutical composition according to Claim 5 or 6, characterized in that the nonionic hydrophilic surfactant is poloxamer 407.

8. Pharmaceutical composition according to one of Claims 1 to 7, characterized in that the nonionic hydrophilic agent is present in a proportion of from 1% to 50% by weight of the active principle in base form.

9. Pharmaceutical composition according to Claim 8, in tablet or gelatin capsule form, characterized in that the nonionic hydrophilic surfactant is present in a proportion of from 1% to 20% by weight of the active principle in base form.

10. Pharmaceutical composition according to Claim 9, in tablet or gelatin capsule form, characterized in that the nonionic hydrophilic surfactant is present in a proportion of from 5% to 15% by weight of the active principle in base form.

11. Pharmaceutical composition according to one of Claims 1 to 10, characterized in that it contains from 50 to 500 mg of active principle.

12. Pharmaceutical composition according to Claim 11, in tablet or gelatin capsule form, characterized in that it contains from 200 to 400 mg of active principle.

13. Pharmaceutical composition according to one of Claims 1 to 12, in tablet or gelatin capsule form, characterized in that it contains from 200 to 400 mg of active principle, calculated in base form, and 10% by weight of nonionic hydrophilic surfactant relative to the active principle in base form.

ABSTRACT

The present invention relates to a solid pharmaceutical composition for oral administration characterized in that it comprises a benzofuran derivative with antiarrhythmic activity, or one of the pharmaceutically acceptable salts thereof, as an active principle, and a pharmaceutically acceptable nonionic hydrophilic surfactant optionally in combination with one or more pharmaceutical excipients.


200
180
160
140
120
100
80
60
40
20
0
CONCENTRATION (ng/ml)
0
6
12
18
24
TIME (hours)
GELATIN CAPSULE
TABLET α
TABLET C
TABLET A

FIG. 1


200
180
160
140
120
100
80
60
40
20
0
CONCENTRATION (ng/ml)
0
6
12
18
24
TIME (hours)
GELATIN CAPSULE
TABLET α
TABLET C
TABLET A

FIG. 2

Docket No. IVD994

DECLARATION AND POWER OF ATTORNEY FOR UNITED STATES PATENT APPLICATION

__X__ Original _____ Supplemental _____ Substitute

As a below-named inventor, I hereby declare that:

My residence, citizenship and post office address are given below under my name.

I believe I am an original, first and joint inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Solid pharmaceutical composition containing benzofurane derivatives

the specification of which

____ is attached hereto.

____ was filed on _____ as United States
Application Serial No. _____
and was amended on _____ (if applicable).

__X__ was filed on 19 June 1998 as PCT International
Application No. PCT/FR98/01285
and was amended under PCT Article 19 on _____ (if applicable).

I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge my duty to disclose information of which I am aware which is material to the examination of this application in accordance with Section 1.56 of Title 37 of the Code of Federal Regulations.

I hereby claim foreign priority benefit under Section 119 (a) - (d) of Title 35 of the United States Code of any foreign application(s) for patent or inventor's certificate or of any PCT application(s) designating at least one country other than the United States identified below and also identify below any foreign application(s) for patent or inventor's certificate or any PCT application(s) designating at least one country other than the United States filed by me on the same subject matter and having a filing date before that of the application(s) from which priority is claimed:

			Priority Claimed	
Country	Number	Filing Date	Yes	No
France	97/07795	23 June 1997	X	

I hereby claim benefit under Section 120 of Title 35 of the United States Code of any United States application(s) or PCT application(s) designating the United States identified below and, insofar as the subject matter of each of the claims of this application is not disclosed in said prior application(s) in the manner provided by the first paragraph of Section 112 of Title 35 of the United States Code, I acknowledge my duty to disclose material information of which I am aware as defined in Section 1.56 of Title 37 of the Code of Federal Regulations which occurred between the filing date of the prior application(s) and the national or PCT filing date of this application:

Application Serial No.	Filing Date	Status

I hereby appoint Michael D. Alexander, Reg. No. 36,080; and Paul E. Dupont, Reg. No. 27,438, or any of them my attorneys or agents with full power of substitution and revocation to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

SEND CORRESPONDENCE TO:

Patent Department
Sanofi-Synthelabo Inc.
9 Great Valley Parkway
P.O. Box 3026
Malvern, PA 19355

DIRECT TELEPHONE CALLS TO:

MICHAEL D. ALEXANDER

Telephone No. (610) 889-8802

I hereby declare that all statements made herein and in the above-identified specification of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of first joint inventor: Bernard ABRAMOVICI

Inventor's signature: _____ Date: 03/13/00

Residence: 56, rue du Luminaire, 34990 Juvignac, France FR

Post Office Address: 56, rue du Luminaire, 34990 Juvignac, France

Citizenship: France

2-00 Full name of second joint inventor Jean-Claude GAUTIER

Inventor's signature _____ Date 03/13/00

Residence 13, rue Gustave Courbet ; 34830 Clapiers ; France FR

Post Office Address 13, rue Gustave Courbet ; 34830 Clapiers ; France

Citizenship France

3-00 Full name of third joint inventor Jean-Claude GROMENIL

Inventor's signature _____ Date 03/13/00

Residence 6, La Voie Romaine ; 34560 Montbazin ; France Montbazin FR

Post Office Address 6, La Voie Romaine ; 34560 Montbazin ; France

Citizenship France

4-00 Full name of fourth joint inventor Jean-Marie MARRIER

Inventor's signature _____ Date 03/13/00

Residence Avenue de la Fontvin ; 34970 Lattes ; France FR

Post Office Address Avenue de la Fontvin ; 34970 Lattes ; France

Citizenship France